Last Updated : October 29, 2019
Details
FilesGeneric Name:
Nelarabine
Project Status:
Cancelled
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Atriance
Project Line:
Reimbursement Review
Project Number:
PC0170-000
Strength:
650 mg
Tumour Type:
Leukemia
Indications:
Acute Lymphoblastic Leukemia
Funding Request:
Individuals, aged 1–30 years, newly diagnosed with intermediate- or high-risk (CNS1 or CNS 2) T-ALL, stages II-IV, during upfront therapy.
Review Status:
Cancelled
Sponsor:
Pediatric Oncology Group of Ontario
Clarification:
The Submitter notified pCODR that they will be unable to submit by their original target date and an updated target submission date has not been provided.
Clarification:
Pediatric Oncology Group of Ontario has notified pCODR that they will not be filing the submission.
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : October 29, 2019